Acurx Pharmaceuticals (ACXP) Stock Analysis & Winston Score

Acurx Pharmaceuticals is a small clinical-stage biotech company focused on developing new antibiotics to fight drug-resistant bacterial infections. Its lead drug candidate, ibezapolstat, is designed to treat a dangerous gut infection called *Clostridioides difficile* (C. diff), which commonly affects hospital patients and people who have recently taken antibiotics. The company does not yet sell any products and is working to advance ibezapolstat through clinical trials. Acurx currently has no revenue, as it is still in the research and development phase. It funds its operations through stock offerings and other financing, which is typical for early-stage biotech companies. The company operates primarily in the United States and faces significant risk because most drug candidates fail before reaching the market — and even if ibezapolstat succeeds, Acurx would need to compete against established treatments for C. diff infections. The key milestone to watch is the outcome of ongoing clinical trials, which will determine whether the drug can move closer to potential approval.